Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why I’m a Long-Term Investor in GlaxoSmithKline plc (GSK)

Page 1 of 2

LONDON — Back in 2007, I made the first of several purchases that together built up a small stake in GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) . Then in my early fifties, it seemed a prudent addition to the income-generating portfolio of stocks that I hope will help to secure a comfortable retirement for me.

Nor do I plan on selling the stake. In fact, by the end of this year, I expect my holding in GlaxoSmithKline to be even larger.

In short, I’m a long-term investor in the company and see it as a core part of my retirement strategy.

So let’s briefly review why, and discuss the merits that I see in a holding of GlaxoSmithKline.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Income generation
Priced today at 1,456 pence, GlaxoSmithKline’s shares are on a forecast price-to-earnings ratio of 12, which is around the market’s average. But the forecast yield is decidedly higher — at 5.3%, it’s around 50% more than the market average.

Income growth
Over the last 10 years, GlaxoSmithKline has grown its dividend at a compound rate of 4.9% a year. Now, that’s not “shoot the lights out” territory, but it’s still a decent track record — and one that in more recent times has also been comfortably exceeded. Roll the clock forward and if that growth is maintained, then in a further 10 years’ time my income will be 60% higher than it is today.

Defensive qualities
Better still, that income looks set to be sustainable, thanks to GlaxoSmithKline’s strong showing in both health care and consumer products. Significantly, the company’s dividend held up during the credit crunch and ensuing recession on 2008, when many companies cut their payouts to investors.

Employing around 99,000 people and manufacturing almost 4 billion packs of medicines and health care products every year, the company is also a consumer business with a robust collection of strong brands: Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums, Zovirax — and, of course, the Macleans range of toothpaste, mouthwash, and toothbrushes.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!